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Abstract
Background: To get insight in the prevalence of high, or low/no serum infliximab trough levels in patients with
low disease activity and if serum trough levels are stable and reliable longitudinally we conducted a prospective
cohort study
Methods: In a longitudinal, observational cohort of RA patients treated with infliximab for at least 6 months,
treatment interval, DAS28, infliximab trough levels and anti-infliximab antibodies were assessed. Prevalence of low
(<1 mg/l) and high (>5 mg/l) infliximab serum trough levels and anti-infliximab antibodies was recorded.
Relationship of a change in anti-infliximab antibodies and treatment interval was described. Reliability of
consecutive infliximab serum trough levels and anti-infliximab antibodies in patients with stable DAS28 and
treatment was analysed with Spearman correlation and kappa-analysis.
Results: 147 patients with a mean disease duration of 11 years (sd7) and DAS28 of 3.5 (sd1.3) at baseline were
followed during 1.5 years. Inter-individual variability in infliximab levels in patients with low DAS28 was high
(median 1.4 mg/L, IQR 3.35), with 31% (95%CI: 20-42%) having low (<1 mg/L) and 14% (95%CI 5–22) high trough
levels (>5 mg/L). Interestingly also in RA patients with DAS28≤ 3.2, anti-infliximab antibodies were found in
one-third of the patients, with half of them having antibodies every visit during a median of more than one year.
Agreement for consecutive measurements of serum trough levels and anti-infliximab antibodies was high in stable
patients: r = 0.97 (p = 0.00001) and kappa = 1.0 (SE 0.14) Anti-infliximab antibody appearance was influenced by
interval increases (relative risk (RR) 5.2, 2.6-10.7), but patients still showed low infliximab levels.
Conclusions: Low (and high) infliximab serum trough levels are prevalent, interestingly also in patients with low
disease activity. Consecutive measurements of serum trough levels and anti-infliximab antibodies are reliable in
stable patients. These test could be used to lower or stop infliximab in selected patients.
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Background
Infliximab, a chimeric (human-mouse) monoclonal anti-
body to human tumour necrosis factor-α (TNF-α), has
proved to be effective in the treatment of rheumatoid
arthritis (RA) in several pivotal randomised controlled
trials [1,2]. There is however a difference in response
between individual RA patients, both in the initiation
and in the maintenance phase. Differences in response
to infliximab in the initiation phase could be partly
explained by inter-individual differences in pharmaco-
kinetics as reflected in lower infliximab trough levels
and presence of anti-infliximab antibodies in patients
not responding to infliximab [3-7].
In the maintenance phase of treatment with infliximab
there are still large inter-individual differences in disease
activity, as witnessed by the relatively high mean and
large variation in disease activity scores (mean DAS28 in
the DREAM registry after one year was about 4) and
large proportion of patients with high disease activity in
biological registries (for example about 45% in the NOR-
DMARD database had a DAS28 > 3.2 after 6 months)
[8,9]. This can be explained by inadequate initial
response, but also by the occurrence of secondary loss of
response after initial improvement on infliximab. There-
fore further improvement of treatment regimens seems
warranted.
The first optimisation would of course be to switch
patients not doing well to another biological. Another
form of treatment optimisation, however, could be low-
ering the dose or stopping infliximab in patients in
whom infliximab is either given in a too high dose, or in
whom the drug is no longer effective. Indeed, stop or
dose reduction studies have shown that this is feasible in
a large proportion of patients [10-12]. It would be very
helpful when successful dose reduction or stopping
could be predicted in these patients, to prevent unneces-
sary flares. Such a predictor is however not yet available.
Recently several studies also demonstrated the poten-
tial use of monitoring of pharmacokinetics during the
maintenance phase of infliximab treatment in RA
patients, next to the initiation phase [13-16]. Therefore,
an interesting possible predictor for successful dose
tapering could be infliximab serum trough levels and
anti-infliximab antibody levels. It can be conceived that
patients with very high serum trough levels of infliximab
could be carefully dose reduced, and that on the other
hand patients without detectable infliximab trough levels
(or anti-infliximab antibodies) could even stop the drug
without deterioration of disease activity. However, there
is not much data on the potential value of measuring
serum trough levels and anti-infliximab antibodies to
guide infliximab treatment in daily clinical practice dur-
ing the maintenance phase. Therefore, to get insight in
the prevalence and course of infliximab serum trough
levels and anti-infliximab antibodies in patients with low
disease activity, we conducted a prospective observa-
tional longitudinal cohort study focussing on two re-
search questions:1) what is the prevalence of high, or
low/no serum infliximab trough levels in patients with
low disease activity? 2) Are these serum trough levels
stable and reliable longitudinally, also in the context of
treatment interval changes?
Methods
Patients and measurements
All RA patients treated for at least 6 months (mainten-
ance phase) with infliximab in daily clinical practice at
the Sint Maartenskliniek, Nijmegen, The Netherlands
were included in a longitudinal observational cohort
during a 1.5 year period or until treatment was discon-
tinued. Enrolment of patients in this dynamic cohort
started in February 2007. All patients received 3 mg/kg,
with infusion intervals varying from 4–12 weeks. Deci-
sions on interval variation were made by the treating
rheumatologist who was blinded for the results of the
serum trough levels and anti-infliximab antibodies, but
according to local treatment protocol a DAS28 was mea-
sured every visit and rheumatologists were advised to
shorten the interval or change therapy if the DAS28 was
more than 3.2 during 2 visits or lengthen the interval if
the DAS28 was less than 2.6 during at least half a year.
According to local protocol intervals were allowed to
vary between 4–12 weeks. At every visit immediately be-
fore infusion sera were collected. Serum trough levels
and anti-infliximab antibodies were measured as
described elsewhere in one batch after the study had
ended [6,7]. Low levels were defined as <1.0 mg/L and
high levels as >5.0 mg/L. Both cut-offs are in accordance
with previous reported thresholds [6].
Approval from the Medical Research Ethics Commit-
tee (MREC) was sought for. The committee decided that
this approval was not necessary because DAS28 guided
dose adaptation was performed as usual care for all
patients meeting the requirements of the Dutch legisla-
tion and no extra venous puncture was necessary.
Informed consent for the extra blood sample and use of
medical and demographic data was obtained from all
patients.
Statistical analyses
Descriptive statistics were provided using mean (+/− stan-
dard deviation (SD)) or median (interquartile range(IQR))
values depending on the (non-) parametric distribution of
measured patient characteristics. We explored our data by
describing the following variables at study enrolment:
prevalence of remission (defined as DAS28≤2.6), low
(DAS28≤3.2) and high (DAS28>3.2) disease activity state,
low (<1.0 mg/L) and high (>5.0 mg/L) infliximab serum
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trough levels and presence of anti-infliximab antibodies
[6,7]. Also the percentage of visits with low disease activity
and remission was described. Additionally, the prevalence
of low serum trough levels and anti-infliximab antibodies
was confirmed in a subgroup of patients with long duration
of stable low disease activity, defined as a DAS28≤3.2 for
at least 3 consecutive visits. Furthermore, the course of
anti-infliximab antibodies during follow up was investigated
longitudinally. The influence of an increase in interval on
anti-infliximab antibody occurrence and the influence of a
shorter interval on anti-infliximab antibody disappearance
were analysed by means of relative risk ratios (RR). Con-
comitant methotrexate (MTX) use was taken into account
in the analysis using relative risk ratios as well.
Finally, we also aimed to establish within-patient reliabil-
ity of infliximab serum trough levels and anti-infliximab
antibodies. To investigate this, infliximab serum trough
levels measured at 2 consecutive visits in patients with
stable DAS28 and stable treatment were compared with a
Wilcoxon test and a spearman correlation test. Further-
more, mean difference and limits of agreement (LoA) were
calculated [17]. The reliability of anti-infliximab antibodies
was determined by kappa test statistic. All analyses were
done with STATA 10.1 statistical software.
Results
Patient characteristics and infliximab serum trough levels
In total 1320 visits in 147 patients treated with infliximab
for at least 6 months were collected in the observation
period. Demographic data at study enrolment is depicted in
Table 1. In 27% (95% confidence interval (CI): 20-34%) and
44% (95%CI:36-52%) of the patients the DAS28 was below
2.6 or 3.2 respectively. As demonstrated in Table 2, at study
enrolment, low infliximab serum trough levels are prevalent
in patients with DAS28>3.2 (48%, 95%CI: 37–59), but
interestingly also in patients with low disease activity (31%,
95%CI: 20–42). In 14% of the patients with low DAS28 and
in 21% of the patients with high DAS28 high infliximab
serum trough levels were found (see Table 2).
Low infliximab serum trough levels in patients with long
term low disease activity
Since at study enrolment a relatively high percentage of
low infliximab serum trough level was found in patients
with low disease activity, we examined whether the pres-
ence of low serum trough levels was persistent in patients
with stable low disease activity. During follow-up of
1.5 years 68 patients complied with the criterion of having
a stable DAS28<3.2 during at least 3 visits. Indeed we
found that 34% (95% CI: 23-46%) of the patients in this
subgroup had consecutively low trough levels, with 41% of
them showing anti-infliximab antibodies. Mean infusion
interval in these patients was 8.1 weeks (sd 2.05) and no
interval changes occurred.
Presence of anti-infliximab antibodies
Anti-infliximab antibodies were found in 18% of all 1320
visits (95%CI:16–20) and 49 of the 147 RA patients
(33%, 95%CI:26–41) had anti-infliximab antibodies at
least once during follow up. There was no significant as-
sociation between MTX use and anti-infliximab anti-
bodies as calculated by RR (0.75, 95%CI = 0.47-1.21,
p = 0.25). In 22 out of 49 patients (45%) anti-infliximab
antibodies were persistently found every visit. These
patients had a median observation period of 58 weeks
(IQR: 8–74) and a mean DAS28 of 3.2 (sd1.2). During
follow up, 14 of the patients with anti-infliximab anti-
bodies discontinued infliximab for the following reasons:
ineffectiveness (n = 10, n = 2 also had an allergic reac-
tion), allergic reaction (n = 1), malignant disease (n = 1),
pregnancy wish (n = 1), other side effect (n = 1). In con-
trast 26 patients without anti-infliximab antibodies dis-
continued of whom 16 because of ineffectiveness.
There were 27 patients with intermittent anti-infliximab
antibodies (median of 3 subsequent visits (IQR: 1–7)). The
RR for the emerging of anti-infliximab antibodies after
interval increase was 5.2 (95%CI 2.6-10.7, p <0.0001). After
interval decrease the RR for disappearing of anti-infliximab
antibodies was 4.9 (95%CI 2.5-9.4, p <0.0001). Interval
changes occurred in 235 of the 1320 visits, of which 125
were interval increases. In 11 visits the interval increase
was followed by anti-infliximab antibody emergence. Inter-
val decreases occurred in 110 visits, with subsequent dis-
appearance of anti-infliximab antibodies in 12 visits.
Reliability of infliximab serum trough levels and
anti-infliximab antibodies
A small and non-significant mean difference in trough
levels was found between two consecutive visits in
Table 1 Baseline characteristics of all patients in the
follow up cohort
Number of patients 147
Age, years (mean, sd*) 58 (12)
Female, No (%) 101 (69)
Weight, kg (mean, sd) 73 (14)
Disease duration, years (mean, sd) 11 (7)
RF positive, No (%) 117 (81)
Anti-CCP positive, No (%) 95 (69)
DAS28 at inclusion (mean, sd) 3.5 (1.3)
Interval duration at inclusion, weeks (median, IQR) 8 [4-8]
Previous DMARDs, weeks (median, IQR**) 3 [2,3]
Concomitant DMARD use, No (%) 111 (78)
Concomitant MTX use, No (%) 95 (67)
Previous anti-TNF-alpha therapy, No (%) 16 (11)
Duration of infliximab therapy, years (mean, sd) 2.5 (2.0)
* sd = standard deviation.
** IQR= interquartile range.
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patients with stable DAS28 and treatment (−0.26,
p = 0.38), with relatively small LoA of −3.6 to 3.11. When
considering serum trough levels in the relevant range of
0-5 mg/L, LoA were even smaller (−0.9 – 0.8), with a
mean difference of −0.04. Agreement between serum
trough levels analysed by spearman correlation was 0.97
(p = 0.00001, Figure 1). For anti-infliximab antibodies the
correlation between subsequent visits was perfect with a
kappa of 1.0 (standard error (SE) 0.14).
Discussion
In our prospective observational longitudinal cohort
study of RA patients treated with infliximab in the main-
tenance phase we encountered several interesting find-
ings concerning the relation between disease activity,
infliximab serum trough levels and anti-infliximab anti-
bodies, and the influence of treatment interval changes.
First of all, low infliximab serum trough levels (with/
without anti-infliximab antibodies) are prevalent in
well-controlled RA patients treated with infliximab dur-
ing the maintenance phase (about 1/3 of the patients).
Since most articles on serum trough levels and anti-
infliximab antibodies are describing the relation be-
tween low levels and non-response and high levels and
good-response, this might seem a counterintuitive
result. Nevertheless when examining these other studies
one can also appreciate that a considerable proportion
of patients with good response or low DAS28 has no
measurable trough level of infliximab or have anti-
infliximab antibodies (for example Pascual-Salcedo et al.
also described that 24% of EULAR good-moderate
responders to infliximab had anti-infliximab antibodies)
[13]. Pondering on these findings it could be hypothe-
sised that the low disease activity in these patients might
not be attributed to infliximab. The initial response of
infliximab in the induction phase of the treatment in
these patients could be explained by a temporary need
for infliximab, placebo response, regression to the mean
or effects of co-medication.
There are some counterarguments against this line of
reasoning. One could argue, for example, that the inflixi-
mab effect is (partially) determined by peak levels or
time integrated area under the curve (AUC) rather than
by minimal inhibitory concentration (MIC). This seems
unlikely as subcutaneous anti-TNF agents demonstrate
similar efficacy compared to intravenous anti-TNF with-
out peak levels [18]. Also, it could be conceived that low
infliximab serum levels and anti-infliximab antibodies
just before the next infusion isn’t a good proxy for low
serum levels or anti-infliximab antibodies during the
majority of the treatment interval. However, Van den
Bemt et al. demonstrated that anti-infliximab antibodies
at the end of the interval is strongly associated with
anti-infliximab antibodies or low/non-measurable serum
levels in between infusions, indicating that low or no
infliximab exposure was present during most of the
treatment interval [19]. Nevertheless, whether RA
patients with low infliximab serum trough levels can
really de-escalate or stop treatment needs confirmation
by means of an intervention study. Of note, high inflixi-
mab serum trough levels also occur relatively frequent.
This may identify patients in whom the infliximab dose
can be reduced whilst maintaining clinical efficacy.
A second finding was that reliability for consecutive
measurements of serum trough levels and anti-
infliximab antibodies of both infliximab levels and anti-
infliximab antibody status was found to be very high.
Table 2 Percentage of low and high infliximab serum trough levels and presence of anti-infliximab antibodies in
patients with low and high DAS28 at the first study visit
No infliximab serum
trough level
Low* infliximab
trough levels
Intermediate infliximab
trough levels
High** infliximab
trough levels
Anti-infliximab
antibodies
Total
DAS28 % (95%CI) % (95%CI) % (95%CI) % (95%CI) % (95%CI) No
patients
<2.6 13 (2–23) 23 (10–35) 48 (32–63) 18 (6–29) 13 (2–23) 40
≤3.2 13 (4–20) 18 (9–28) 55 (43–67) 14 (5–22) 11 (3–19) 65
>3.2 29 (19–39) 18 (10–27) 32 (22–42) 21 (12–30) 29 (19–39) 82
* Low serum trough levels are defined as <1.0 mg/L.
** High serum trough levels are defined as >5.0 mg/L.
Figure 1 Serum trough levels measured at 2 consecutive visits
in RA patients with stable DAS28 and infliximab dosing.
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Reliable measurements are essential before considering
measuring infliximab serum trough levels and anti-
infliximab antibodies in daily clinical practice.
With regard to the anti-infliximab antibodies it should
be noted that, although one-third of the patients had de-
tectable antibodies during at least one visit, in only half
of these patients they were found consistently every visit.
Since the level of anti-infliximab antibodies is the result-
ant of antibody formation and (antigen-bound) antibody
clearance, a change in infusion interval (thus a change in
antigen challenge) might explain why in some patients
anti-infliximab antibodies were only measurable tempor-
arily. Indeed, after increasing the infusion interval anti-
infliximab antibodies were found more frequently as can
be concluded based on the RR. However, we have shown
that, although anti-infliximab antibody status might
change, most of these patients still have very low serum
infliximab trough levels in between visits without anti-
bodies. In addition our data failed to confirm the
relationship between methotrexate use and reduced oc-
currence of anti-infliximab antibodies, which could well
be due to a lack of statistical power[3].
Finally, our study confirmed earlier data that adequate
disease control in daily clinical practice is often not
reached, as demonstrated by less than half of the
patients having a DAS28 below or equal to 3.2. Although
the effect of tight control is well established [20,21] and
a local protocol encouraged and facilitated physicians to
change treatment if disease activity was inadequately
controlled, still half of the patients didn’t reach the treat-
ment target. This finding, that is concordant with find-
ings in other biologic cohorts, underscores the need for
better implementation strategies in daily clinical practice
of tight control based treatment.
Conclusions
In conclusion, our study demonstrated that measuring
infliximab serum trough levels and anti-infliximab anti-
bodies during the maintenance phase of infliximab treat-
ment could be of value to optimise treatment. Low (and
to some extent high) infliximab serum trough levels are
prevalent in RA patients treated for a longer time with
infliximab, also in patients with low disease activity.
Since infliximab serum trough levels and anti-infliximab
antibodies are reliable measurements, these might be
used to identify patients in whom infliximab can be de-
escalated or stopped.
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